Karl Heath

2.2k citations

14 papers · 1.6k indexed · 1 hit paper · h-index 9

Impact in

Otorhinolaryngology top 1%
- Head and Neck Cancer Studies
Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies

Papers in

Otorhinolaryngology 2
- Head and Neck Cancer Studies 2
Oncology 10
- Cancer Immunotherapy and Biomarkers 9
- CAR-T cell therapy research 3

Co-authors: Raanan Berger Jared Lunceford Jonathan D. Cheng Barbara Burtness Tanguy Y. Seiwert Laura Q.M. Chow Ranee Mehra Joseph P. Eder
Journals: Journal of Clinical Oncology (8 papers)Blood (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)The Journal of Urology (1 paper)The Lancet Oncology (1 paper)
Partner nations: United States Israel United Kingdom

In The Last Decade

Karl Heath

13 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial 2016 · 1.3k citations

Peers

Countries citing papers authored by Karl Heath

Since Specialization

Citations

This map shows the geographic impact of Karl Heath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Heath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Heath more than expected).

Fields of papers citing papers by Karl Heath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Heath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Heath. The network helps show where Karl Heath may publish in the future.

Co-authors

The 25 scholars most cited alongside Karl Heath, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Karl Heath Line = papers co-authored together Karl Heath links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial The Lancet Oncology ·Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph P. Eder, Karl Heath, Terrill K. McClanahan, Jared Lunceford, Christine K. Gause, Jonathan D. Cheng, Laura Q.M. Chow Hit paper breakdown →	2016	1275
2	Phase 1/2 study of pembrolizumab (pembro) in children with advanced melanoma or a PD-L1-positive (PD-L1⁺) advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051). Journal of Clinical Oncology ·Birgit Geoerger, Elizabeth Fox, Alberto S. Pappo, Ana Filipa Ferreira, Lynley V. Marshall, Karl Heath, Scott J. Diede, Scot Ebbinghaus, Julie R. Park	2016	0
3	2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012 European Journal of Cancer ·Laura Q.M. Chow, Ranee Mehra, Bartosz Doktór, Jelliffe, Paula Jaén-Moreno, Norio Horiike, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, D. Le, Julia N. Cheng, Karl Heath, Kumudu Pathiraja, Tanguy Y. Seiwert	2015	6
4	Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Journal of Clinical Oncology ·Tanguy Y. Seiwert, Robert I. Haddad, Shilpa Gupta, Ranee Mehra, Makoto Tahara, Raanan Berger, Se‐Hoon Lee, Barbara Burtness, Dung T. Le, Karl Heath, Amy E. Blum, Marisa Dolled‐Filhart, Kenneth Emancipator, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q.M. Chow	2015	74
5	Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475). Journal of Clinical Oncology ·Veena Shankaran, Kei Muro, Yung‐Jue Bang, Ravit Geva, Daniel Virgil Thomas Catenacci, Shilpa Gupta, Joseph P. Eder, Raanan Berger, Andrey Loboda, Andrew Albright, Răzvan Cristescu, Erin Murphy, Terri McClanahan, Mark Ayers, Michael Nebozhyn, Jared Lunceford, Minori Koshiji, Karl Heath, Jonathan D. Cheng, 冯金环	2015	21
6	Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study. Journal of Clinical Oncology ·Peter H. O’Donnell, Elizabeth R. Plimack, Joaquim Bellmunt, Raanan Berger, Bruce Montgomery, Karl Heath, Marisa Dolled‐Filhart, Kumudu Pathiraja, Christine K. Gause, Jonathan D. Cheng, Rodolfo F. Perini, Shilpa Gupta	2015	24
7	Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. Journal of Clinical Oncology ·Elizabeth R. Plimack, Joaquim Bellmunt, Shilpa Gupta, Raanan Berger, Bruce Montgomery, Karl Heath, Jonathan Juco, Kenneth Emancipator, Kumudu Pathiraja, Jared Lunceford, Rodolfo F. Perini, Peter H. O’Donnell	2015	90
8	Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Journal of Clinical Oncology ·Tanguy Y. Seiwert, Robert I. Haddad, Shilpa Gupta, Ranee Mehra, Makoto Tahara, Raanan Berger, Se‐Hoon Lee, Barbara Burtness, Dung T. Le, Karl Heath, Amy E. Blum, Marisa Dolled‐Filhart, Kenneth Emancipator, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q.M. Chow	2015	12
9	Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. Journal of Clinical Oncology ·Tanguy Y. Seiwert, Barbara Burtness, Jared Weiss, Joseph P. Eder, Jennifer H. Yearley, Erin Murphy, Michael Nebozhyn, Terri McClanahan, Mark Ayers, Jared Lunceford, Ranee Mehra, Karl Heath, Jonathan D. Cheng, Laura Q.M. Chow	2015	37
10	MP68-11 A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED UROTHELIAL CANCER The Journal of Urology ·Shilpa Gupta, Peter H. O’Donnell, Elizabeth R. Plimack, Norio Horiike, Bruce Montgomery, Karl Heath, Marisa Dolled‐Filhart, Kumudu Pathiraja, Christine K. Gause, Jonathan Cheng, Rodolfo F. Perini, Joaquim Bellmunt	2015	7
11	A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology ·David S. Siegel, Philippe Moreau, David Avigan, Kenneth C. Anderson, Donna Reece, Jesús F. San Miguel, María‐Victoria Mateos, Dianna Wu, Kenneth Emancipator, Marisa Dolled‐Filhart, Christine K. Gause, Holly Brown, Karl Heath, Robert Iannone, Shelonitda Rose, Robert Z. Orlowski	2014	6
12	Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC) Cancer Chemotherapy and Pharmacology ·Hielke J. Meulenbeld, Johann S. de Bono, Scott T. Tagawa, Young E. Whang, Xiaoyun Li, Karl Heath, Anthe S. Zandvliet, Scot Ebbinghaus, Gary R. Hudes, Ronald de Wit	2013	20
13	Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma:in vitroand phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition Leukemia & lymphoma ·Reinhard Dummer, Marc Beyer, Kenneth B. Hymes, Mirjam T. Epping, René Bernards, Matthias Steinhoff, Wolfram Sterry, Helmut Kerl, Karl Heath, А. В. Локтєв, James S. Hardwick, J. Garcia‐Vargas, Katrin Baumann, Syed Rizvi, Stanley R. Frankel, Sean Whittaker, Chalid Assaf	2012	51
14	A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results Blood ·Guillermo Garcia‐Manero, Lewis B. Silverman, Ivana Gojo, Laura C. Michaelis, Simrit Parmar, Stuart L. Goldberg, Hagop M. Kantarjian, J. Garcia‐Vargas, Syed Rizvi, Karl Heath, Azra Raza	2008	5

About Karl Heath

Karl Heath is a scholar working on Otorhinolaryngology, Oncology, Hematology, Immunology and Cancer Research, having authored 14 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (3 papers), Bladder and Urothelial Cancer Treatments (3 papers), Immunotherapy and Immune Responses (2 papers), Multiple Myeloma Research and Treatments (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Head and Neck Cancer Studies (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Otorhinolaryngology (386 citations), Oncology (1.3k citations), Immunology (490 citations), Pulmonary and Respiratory Medicine (453 citations) and Cancer Research (189 citations). Karl Heath has collaborated with scholars based in United States, Israel and United Kingdom. Frequent co-authors include Raanan Berger, Jared Lunceford, Jonathan D. Cheng, Barbara Burtness, Tanguy Y. Seiwert, Laura Q.M. Chow, Ranee Mehra, Joseph P. Eder, Jared Weiss and Christine K. Gause. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer Chemotherapy and Pharmacology, The Journal of Urology and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact